BRN 1723530
BRN 1723530 Brand names, BRN 1723530 Analogs
- (+)-Aspartic acid
- (2S)-Aspartic acid
- (L)-ASPARTIC ACID
- (S)-Aminobutanedioic acid
- (S)-Aspartic acid
- 4-04-00-02998 (Beilstein Handbook Reference)
- AI3-04461
- Acide aspartique [INN-French]
- Acido aspartico [INN-Spanish]
- Acidum asparticum
- Acidum asparticum [INN-Latin]
- Aminosuccinic acid
- Asparagic acid
- Asparagic acid (VAN)
- Asparaginic acid
- Asparaginic acid (VAN)
- Asparaginsaeure [German]
- Aspartate
- Aspartate, L-
- Aspartic Acid [USAN:INN]
- Aspartic acid
- Aspartic acid (VAN)
- Aspartic acid, L-
- Aspatofort
- BRN 1723530
- Butanedioic acid, amino-, (S)-
- CCRIs 6181
- EINECS 200-291-6
- FEMA No. 3565
- H-Asp-OH
- HSDB 1430
- L( )-Aminobernsteinsaeure
- L-(+)-Aspartic acid
- L-2-Aminobutanedioic acid
- L-Aminosuccinic acid
- L-Asparagic acid
- L-Asparaginic acid
- L-Asparaginsaeure
- L-Asparaginsyra
- L-Aspartic acid
- L-Aspartinsaeure
- NSC 3973
BRN 1723530 Brand Names Mixture
- No information avaliable
BRN 1723530 Chemical_Formula
C4H7N1O4
BRN 1723530 RX_link
No information avaliable
BRN 1723530 fda sheet
BRN 1723530 msds (material safety sheet)
BRN 1723530 Synthesis Reference
No information avaliable
BRN 1723530 Molecular Weight
133.104 g/mol
BRN 1723530 Melting Point
230 oC
BRN 1723530 H2O Solubility
4.5 g/l
BRN 1723530 State
Solid
BRN 1723530 LogP
-0.67 +/- 0.36
BRN 1723530 Dosage Forms
Capsules and powder
BRN 1723530 Indication
There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.
BRN 1723530 Pharmacology
L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed.
BRN 1723530 Absorption
Absorbed from the small intestine by an active transport process
BRN 1723530 side effects and Toxicity
Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.
BRN 1723530 Patient Information
No information avaliable
BRN 1723530 Organisms Affected
Humans and other mammals
